Larimar Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 12.99 million compared to USD 9.43 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.21 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 USD | +12.68% | +12.99% | +75.82% |
May. 31 | Health Care Stocks Climb On Drug News -- Health Care Roundup | DJ |
May. 31 | Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.82% | 510M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- LRMR Stock
- News Larimar Therapeutics, Inc.
- Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023